Edition:
United Kingdom

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,647.00GBp
18 Sep 2019
Change (% chg)

-- (--)
Prev Close
1,647.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,797,259
52-wk High
1,767.00
52-wk Low
1,408.80

Latest Key Developments (Source: Significant Developments)

FDA Panel Says Benefits Of GlaxoSmithKline's OTC Nicotine Oral Spray Outweigh Risks
Wednesday, 18 Sep 2019 

Sept 18 (Reuters) - GlaxoSmithKline PLC ::OVER-THE-COUNTER NICOTINE ORAL SPRAY.OVER-THE-COUNTER NICOTINE ORAL SPRAY.OVER-THE-COUNTER NICOTINE ORAL SPRAY; SAYS BENEFITS OUTWEIGH RISKS.  Full Article

Vectura Says $89.7 Mln Award To Co Related To GSK Litigation Upheld
Friday, 13 Sep 2019 

Sept 13 (Reuters) - Vectura Group PLC ::VECTURA GROUP PLC - VECTURA PROVIDES UPDATE ON GSK LITIGATION.VECTURA GROUP PLC - AWARD OF US$89.7M IN DAMAGES TO VECTURA ON MAY 3, 2019 UPHELD.  Full Article

GlaxoSmithKline - FDA Approved Nucala For Use In Children As Young As 6 Years Old With Severe Eosinophilic Asthma
Thursday, 12 Sep 2019 

Sept 12 (Reuters) - GlaxoSmithKline PLC ::NUCALA IS THE FIRST BIOLOGIC APPROVED IN THE US FOR SIX TO 11-YEAR-OLD CHILDREN WITH SEVERE EOSINOPHILIC ASTHMA.GLAXOSMITHKLINE PLC - FDA APPROVED NUCALA (MEPOLIZUMAB) FOR USE IN CHILDREN AS YOUNG AS 6 YEARS OLD WITH SEVERE EOSINOPHILIC ASTHMA.  Full Article

Ionis Licenses Hepatitis B Program To GSK
Tuesday, 27 Aug 2019 

Aug 27 (Reuters) - Ionis Pharmaceuticals Inc ::IONIS LICENSES HEPATITIS B PROGRAM TO GSK.IONIS PHARMACEUTICALS INC - GSK EXERCISES OPTION TO LICENSE PROGRAM FOLLOWING POSITIVE PHASE 2 RESULTS.IONIS PHARMACEUTICALS INC - UNDER AGREEMENT, CO IS ELIGIBLE TO RECEIVE LICENSE FEES, MILESTONE PAYMENTS UP TO $262 MILLION, INCLUDING $25 MILLION LICENSE FEE.IONIS PHARMACEUTICALS INC - ALSO ELIGIBLE TO RECEIVE TIERED ROYALTIES IN LOW DOUBLE DIGITS ON NET SALES AS A PART OF LICENSING AGREEMENT.  Full Article

GSK Long-Acting HIV Injection Meets Goal In Late Stage Study
Thursday, 22 Aug 2019 

Aug 22 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV RESULTS POSITIVE FOR EVERY 2 MONTH INJECTION.GSK- PHASE III STUDY RESULTS OF INVESTIGATIONAL, LONG-ACTING, INJECTABLE HIV-TREATMENT TWO MONTHS REGIMEN ATLAS-2M STUDY MET ITS PRIMARY ENDPOINT.GLAXOSMITHKLINE PLC - DETAILED RESULTS FROM ATLAS-2M STUDY WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING.  Full Article

GSK Submits Regulatory File For Daprodustat In Japan
Wednesday, 21 Aug 2019 

Aug 21 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - GSK SUBMITS REGULATORY FILE IN JAPAN: DAPRODUSTAT.GLAXOSMITHKLINE PLC - GSK SUBMITS FIRST REGULATORY APPLICATION FOR DAPRODUSTAT IN JAPAN FOR PATIENTS WITH RENAL ANAEMIA DUE TO CHRONIC KIDNEY DISEASE.GSK - DAPRODUSTAT LAUNCH ACTIVITIES, INCLUDING ENGAGEMENT OF HEALTHCARE PROFESSIONALS, EXPECTED TO BE CONDUCTED JOINTLY BY KYOWA KIRIN AND GSK.  Full Article

GSK Announces Jack Bailey, President U.S. Pharmaceuticals, Decided To Step Down
Monday, 12 Aug 2019 

Aug 12 (Reuters) - GlaxoSmithKline PLC ::JACK BAILEY, PRESIDENT U.S. PHARMACEUTICALS HAS DECIDED TO STEP DOWN FROM ROLE AT END OF YEAR.BAILEY TO BE SUCCEEDED BY MAYA MARTINEZ-DAVIS.MARTINEZ-DAVIS TO JOIN GSK IN MID-SEPT AND WILL ASSUME RESPONSIBILITY OF THE U.S. PHARMACEUTICALS BUSINESS ON JAN 1, 2020.  Full Article

GlaxoSmithKline Says ViiV Submits Cabotegravir To EMA For HIV Injection
Monday, 29 Jul 2019 

July 29 (Reuters) - GlaxoSmithKline PLC ::VIIV SUBMITS CABOTEGRAVIR TO EMA FOR HIV INJECTION.REGULATORY APPLICATION TO EMA FOR INVESTIGATIONAL CABOTEGRAVIR TO BE USED WITH RILPIVIRINE AS FIRST MONTHLY, INJECTABLE TREATMENT FOR HIV.  Full Article

GSK Unit ViiV Presents 96-Week Data From Phase III HIV-1 Study
Monday, 22 Jul 2019 

July 22 (Reuters) - GlaxoSmithKline PLC ::GLAXOSMITHKLINE PLC - VIIV PRESENTS 96-WEEK DATA FROM PHASE III STUDY.GSK-VIIV, PFIZER, SHIONOGI ANNOUNCED POSITIVE WEEK RESULTS FROM PHASE III BRIGHTE STUDY OF INVESTIGATIONAL FOSTEMSAVIR IN ADULTS WITH HIV-1 INFECTION.GSK- AT LEAST 1 SERIOUS ADVERSE EVENT WAS EXPERIENCED BY 38% OF TOTAL TREATED PATIENTS, COMMON OF WHICH WERE ATTRIBUTED TO INFECTIONS OR INFESTATIONS.GLAXOSMITHKLINE PLC - VIIV HEALTHCARE PLANS TO COMMENCE SUBMISSION OF REGULATORY APPLICATIONS FOR FOSTEMSAVIR, WITH US NDA, LATER THIS YEAR.  Full Article

Shanghai Fosun Pharma's Unit To Buy GlaxoSmithkline Pharmaceuticals (Suzhou)
Monday, 8 Jul 2019 

July 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK::SAYS UNIT SIGNS AGREEMENT TO BUY GLAXOSMITHKLINE PHARMACEUTICALS (SUZHOU) FOR UP TO 250.0 MILLION YUAN ($36.34 million).  Full Article

UK Stocks-Factors to watch on Sept 19

Sept 19 Britain's FTSE 100 index is seen opening 14 points lower at 7,300 on Thursday, according to financial bookmakers. * BP: BP Plc began a planned overhaul on Wednesday of the small gasoline-producing fluidic catalytic cracking unit (FCCU) at its 430,000 barrel-per-day (bpd) Whiting, Indiana, refinery, said sources familiar with plant operations. * GSK: An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of Glaxo